Beximco Group
Business Health

Beximco launches its 5th Blood pressure drug Nadolol in US market

An AIM-listed manufacturer, Beximco Pharma, which is also a subsidiary of Salman F Rahman’s Beximco Group, recently exported its blood drug Nadolol to the US market — a move towards expanding the pharmacy exports from Bangladesh.

With an aim to enhance human health and the overall well-being of society, Beximco Pharma continues to offer contemporary and affordable medicines and has managed to extend its reach to over 45 countries all over the world — as it’s well accredited across multiple global regulatory authorities within the EU, Australia, China and the Middle East. In shaping this, its co-founder Salman F Rahman, who is one of the most successful businessmen in Bangladesh, had a crucial role to play with his constant investment and research projects under Beximco Group.

Talking about the launch of drug Nadolol, Mr. Nazmul Hassan MP, the managing director of Beximco Pharmaceuticals, said that it is our fifth product in the US market, which exhibits the continued progress in expanding our presence in the market.

Bangladesh is currently able to address the unmet medical need with its continuous investments in the production of generic and affordable medicines. In light of this, Salman F Rahman, a dynamic businessman in Bangladesh, added that the local pharmacy companies were meeting 97% of domestic demand at the lowest prices in the world.

Nadolol tablets, the company’s 5th product is expected to boost the pharmacy exports of Bangladesh. They are being considered an equivalent to Bristol —- Myers Squibb’s Corgard tablets for the treatment of chest pain. As per the data of IQVIA, the total market value of Beximco tablets were about $ 63 million—  a surge, as the exports have soared to about 25.60% in the last fiscal year.

Must Read:  Understanding the Importance of a Pharmacy’s Legitimacy

Attaining the consent of the US Food and Drug Administration, Beximco Pharma became the 1st Bangladeshi pharmaceutical company to export the medicines to the US market in the year 2016, after the successful inspection of their oral solid dosage facilities in June 2015.

“Due to our presence and quality development projects in the US and other emerging markets, we are well equipped to achieve double- digit growth in our export business,” Mr. Hassan said.

Leave a Reply

Your email address will not be published. Required fields are marked *